Eurobio Scientific: all resolutions approved at the Annual General Meeting
16 Giugno 2023 - 5:45PM
Eurobio Scientific: all resolutions approved at the Annual General
Meeting
Eurobio Scientific: all
resolutions approved at the Annual General
Meeting
The Board of Directors
appoints a new governance
Paris,
16 June
2023 –
5:45pm
Eurobio Scientific
(FR0013240934, ALERS, PEA-PME eligible), a leading French group in
in vitro specialty medical diagnostics and life sciences, held its
ordinary and extraordinary general meeting of shareholders on 13
June 2023.
At the date of the meeting, the total number of
shares with voting rights was 10,208,224 for an equivalent total
number of voting rights. The 73 shareholders present, represented
or voting by post at this General Meeting, together held 5,156,579
shares, giving a quorum of 50.51%, for the resolutions submitted to
the Ordinary and Extraordinary General Meetings.
All the resolutions approved by the Board of
Directors, both ordinary and extraordinary, were adopted by a very
large majority, in particular :
- approval of the
annual and consolidated financial statements for the year ended 31
December 2022,
- the
appropriation of net profit for the 2022 financial year,
- the
authorisation given to the Board of Directors to implement a share
buyback programme,
- renewal of the
financial authorisations granted to the Board of Directors to carry
out capital increases while maintaining and/or cancelling
shareholders' pre-emptive subscription rights,
- renewal of the
authorisation given to the Board of Directors to cancel shares
previously bought back under the share buyback programme,
- renewal of the
authorisation given to the Board of Directors to grant free shares
to employees and officers of the Company.
Voting details are provided in the appendix on
the next page.
At the Board meeting held after the Annual
General Meeting, the directors also agreed to change the Company's
governance structure with :
- the appointment
of Denis Fortier as Chairman and CEO
- the appointment of three Deputy
CEOs:
- Jean-Michel
Carle
- Anne-Sophie
Hérelle, Finance and Information Systems
- Cathie Marsais,
Operations and Regulatory Affairs
Hervé Duchesne de Lamotte, previously Deputy
CEO, remains a director.
Appendix : voting details
|
Ordinary General Meeting |
Number of votes in favour |
% of votes cast |
Number of votes against |
% of votes cast |
Abstentions |
% of votes cast |
|
1st resolution
(Approval of the financial statements for the year ending 31
December 2022) |
5,067,968 |
98.29% |
88,432 |
1.71% |
179 |
0.00% |
|
2nd resolution
(Approval of the consolidated financial statements for the year
ending 31 December 2022) |
5,156,256 |
100.00% |
144 |
0.00% |
179 |
0.00% |
|
3rd resolution
(Allocation of earnings for the year ended 31 December 2022) |
5,156,256 |
100.00% |
144 |
0.00% |
179 |
0.00% |
|
4th resolution
(Approval of agreements governed by Article L. 225-38 of the French
Commercial Code) |
4,710,872 |
91.79% |
421,452 |
8.21% |
24,255 |
0.47% |
|
5th resolution
(Setting the total annual amount of remuneration allocated to
directors) |
5,043,380 |
97.81% |
112,995 |
2.19% |
204 |
0.00% |
|
6th resolution
(Authorisation for the Board of Directors to implement a programme
to buy back the Company's own shares) |
5,156,256 |
100.00% |
144 |
0.00% |
179 |
0.00% |
|
7th resolution
(Powers) |
5,156,256 |
100.00% |
144 |
0.00% |
179 |
0.00% |
|
Extraordinary General
Meeting |
Number of votes in favour |
% of votes cast |
Number of votes against |
% of votes cast |
Abstentions |
% of votes cast |
|
8th resolution
(Delegation of authority granted to the Board of Directors to
increase the share capital for the benefit of specified categories
of investors) |
3,747,361 |
72.67% |
1,409,218 |
27.33% |
- |
0.00% |
|
9th resolution
(Delegation of authority to the Board of Directors to increase the
number of shares to be issued in the event of a capital increase,
with or without pre-emptive rights) |
3,816,795 |
74.02% |
1,339,784 |
25.98% |
- |
0.00% |
|
10th resolution
(Authorisation to be granted to the Board of Directors to reduce
the Company's share capital by cancelling shares) |
5,014,242 |
97.24% |
142,337 |
2.76% |
- |
0.00% |
|
11th resolution
(Authorisation to be granted to the Board of Directors in view of
the free allocation of new or existing shares in the
Company) |
3,555,088 |
68.94% |
1,601,491 |
31.06% |
- |
0.00% |
|
12th resolution
(Delegation of authority to the Board of Directors to increase the
Company's share capital for the benefit of members of the company
savings scheme) |
4,471,871 |
86.72% |
684,708 |
13.28% |
- |
0.00% |
|
13th
resolution (Powers) |
5,014,242 |
97.24% |
142,337 |
2.76% |
- |
0.00% |
Next financial meetingH1 revenues: July 24,
2023 (after market closes)
|
About Eurobio
ScientificEurobio Scientific is a key player in the field
of specialty in vitro diagnostics. It is involved from research to
manufacturing and commercialization of diagnostic tests in the
fields of transplantation, immunology and infectious diseases, and
sells instruments and products for research laboratories, including
biotechnology and pharmaceutical companies. Through many
partnerships and a strong presence in hospitals, Eurobio Scientific
has established its own distribution network and a portfolio of
proprietary products in the molecular biology field. The Group has
approximately 290 employees and four production units based in the
Paris region, in Germany, in the Netherlands and in the United
States, and several affiliates based in Dorking UK, Sissach
Switzerland, Bünde Germany, Antwerp Belgium,Utrecht in The
Netherlands and Milan in Italy.Eurobio Scientific's reference
shareholder is the EurobioNext holding company which brings
together its two directors, Jean-Michel Carle and Denis Fortier,
alongside the "Pépites et Territoires" by AXA & NextStage AM
investment program, managed by NextStage AM. For more information,
please visit: www.eurobio-scientific.comThe company is publicly
listed on the Euronext Growth market in ParisEuronext Growth BPI
Innovation, PEA-PME 150 and Next Biotech indices, Euronext European
Rising Tech label.Symbol: ALERS - ISIN Code: FR0013240934 -
Reuters: ALERS.PA - Bloomberg: ALERS:FP |
|
Contacts |
|
Groupe Eurobio ScientificDenis Fortier, Chairman
and CEOAnne-Sophie Hérelle, Deputy CEO Finance & ITTel. +33(0)
1 69 79 64 80 |
CalyptusMathieu CalleuxInvestors RelationsTel.
+33(1) 53 65 68 68 - eurobio-scientific@calyptus.net |
- 230616PR-Eurobio Scientific AG 2023_EN
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Nov 2023 a Nov 2024
